Gilead Sciences has agreed to get Immunomedics for about $21 billion, giving it a opportunity blockbuster breast cancer drug to incorporate to its oncology pipeline.

The U.S. Food stuff and Drug Administration granted accelerated acceptance in April to Immunomedics’ Trodelvy remedy for individuals with metastatic triple-negative breast cancer (mTNBC).

“As a first out there remedy for cancer individuals who absence effective selections, yearly gross sales of Trodelvy are expected to reach $2.3 billion by 2026,” according to The Motley Idiot.

Gilead, which is ideal known for antiviral remedies, said Sunday it will pay back $88 for every share for Immunomedics, a premium of 108% to Friday’s closing rate.

“This acquisition represents significant progress in Gilead’s perform to build a potent and various oncology portfolio,” Gilead CEO Daniel O’Day said in a news launch. “Trodelvy is an permitted, transformational medication for a type of cancer that is particularly demanding to treat.”